###begin article-title 0
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling
###end article-title 0
###begin p 1
K.S. Bak-Jensen's present address is Dept. of Diabetes Protein Engineering, Novo Nordisk A/S, DK-2760 Malov, Denmark.
###end p 1
###begin p 2
B.S. McKenzie's present address is CSL Ltd. Bio21 Institute, Parkville, Victoria, Australia 3020.
###end p 2
###begin p 3
Daniel J. Cua and Rene de Waal Malefyt contributed equally to this paper.
###end p 3
###begin p 4
###xml 335 340 <span type="species:ncbi:9606">human</span>
###xml 345 351 <span type="species:ncbi:10090">murine</span>
###xml 394 399 <span type="species:ncbi:9606">human</span>
Prostaglandins, particularly prostaglandin E2 (PGE2), play an important role during inflammation. This is exemplified by the clinical use of cyclooxygenase 2 inhibitors, which interfere with PGE2 synthesis, as effective antiinflammatory drugs. Here, we show that PGE2 directly promotes differentiation and proinflammatory functions of human and murine IL-17-producing T helper (Th17) cells. In human purified naive T cells, PGE2 acts via prostaglandin receptor EP2- and EP4-mediated signaling and cyclic AMP pathways to up-regulate IL-23 and IL-1 receptor expression. Furthermore, PGE2 synergizes with IL-1beta and IL-23 to drive retinoic acid receptor-related orphan receptor (ROR)-gammat, IL-17, IL-17F, CCL20, and CCR6 expression, which is consistent with the reported Th17 phenotype. While enhancing Th17 cytokine expression mainly through EP2, PGE2 differentially regulates interferon (IFN)-gamma production and inhibits production of the antiinflammatory cytokine IL-10 in Th17 cells predominantly through EP4. Furthermore, PGE2 is required for IL-17 production in the presence of antigen-presenting cells. Hence, the combination of inflammatory cytokines and noncytokine immunomodulators, such as PGE2, during differentiation and activation determines the ultimate phenotype of Th17 cells. These findings, together with the altered IL-12/IL-23 balance induced by PGE2 in dendritic cells, further highlight the crucial role of the inflammatory microenvironment in Th17 cell development and regulation.
###end p 4
###begin p 5
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 726 727 722 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
Prostaglandins, prostaglandin E2 (PGE2) in particular, play an important role in the regulation of inflammatory responses. PGE2 is a key mediator of pyrexia, hyperalgesia, and arterial dilation, which increases blood flow to inflamed tissues and, in combination with enhanced microvascular permeability, results in edema. The relevance of this pathway in promoting inflammation is supported by the clinical use of cyclooxygenase inhibitors, which interfere with prostaglandin synthesis and are used as effective antiinflammatory agents (1). However, PGE2 can also exert antiinflammatory properties and is a negative regulator of neutrophil, monocyte, and lymphocyte function, particularly of Th1 cells that produce IFN-gamma (2). This apparent paradox has puzzled many investigators for decades. The interplay among PGE2, IL-23, and IL-1beta biology may now provide an explanation of this paradox.
###end p 5
###begin p 6
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 418 419 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 421 423 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 425 427 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 557 559 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 400 405 <span type="species:ncbi:9606">human</span>
Th17 cells have been recognized as a unique subset of effector T cells that are distinct from the Th1 and Th2 subsets (3-6), and they have been implicated as potent effectors of autoimmune disorders, such as multiple sclerosis, psoriasis, arthritis, and inflammatory bowel disease (IBD) (7-10). We and others have previously reported that IL-23 and IL-1beta are crucial factors during development of human Th17 cells (9, 11, 12). In addition, IL-23 and the IL-23-dependent Th17 cell population play essential roles in chronic inflammation and autoimmunity (13).
###end p 6
###begin p 7
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 354 356 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 542 543 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 551 553 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 71 77 <span type="species:ncbi:10090">murine</span>
###xml 441 446 <span type="species:ncbi:9606">human</span>
###xml 623 628 <span type="species:ncbi:9606">human</span>
PGE2 has been shown to exacerbate inflammation and disease severity in murine models of IBD and collagen-induced arthritis through the IL-23-IL-17 pathway (14, 15). These effects have been attributed to actions of PGE2 on innate cells, as PGE2 enhances the production of IL-23 and IL-1beta in macrophages and DCs, while down-regulating IL-12 production (16). A recent report has shown that PGE2, together with IL-23, favors the expansion of human Th17 cells from PBMCs, and that PGE2 enhances IL-17 production induced by IL-23 from memory CD4+ cells (17). However, the molecular mechanism of PGE2-mediated signaling during human Th17 cell development has not yet been examined.
###end p 7
###begin p 8
###xml 533 534 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 536 538 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 65 71 <span type="species:ncbi:10090">murine</span>
###xml 145 150 <span type="species:ncbi:9606">human</span>
In this study, we show that PGE2 acts directly on both human and murine T cells to enhance Th17 development and effector cytokine production. In human T cells, PGE2 acts via the prostaglandin receptor EP2- and EP4-mediated signaling and cAMP pathways to up-regulate IL-23 and IL-1 receptor expression. Furthermore, PGE2 synergizes with IL-1beta and IL-23 to drive retinoic acid receptor-related orphan receptor (ROR)-gammat, IL-17, IL-17F, CCL20, and CCR6 expression, which is consistent with the previously reported Th17 phenotype (8, 18). While enhancing Th17 cytokine expression mainly through EP2, PGE2 differentially regulates IFN-gamma production and inhibits production of the antiinflammatory cytokine IL-10 in both naive and memory Th17 cells predominantly through EP4. Hence, the combination of inflammatory cytokines and noncytokine immunomodulators, such as PGE2, during differentiation and activation determines the ultimate phenotype of Th17 cells. These findings, together with the altered IL-12/IL-23 balance induced by PGE2 in dendritic cells, further highlight the crucial role of the inflammatory microenvironment in Th17 cell development and regulation.
###end p 8
###begin title 9
RESULTS
###end title 9
###begin title 10
PGE2 up-regulates IL-23 and IL-1 receptor expression on naive T cells via EP2, EP4, and cAMP signaling
###end title 10
###begin p 11
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 425 428 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 433 436 433 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 578 586 578 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 673 676 673 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 838 841 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 846 849 843 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 120 125 <span type="species:ncbi:9606">Human</span>
To study the effects of PGE2 on T cells, we first analyzed the expression of the PGE2 receptors EP1, EP2, EP3, and EP4. Human naive CD4+CD45RA+ T cells were isolated from peripheral blood of healthy donors, as previously described (9). The purity of these naive T cell populations was routinely >99.5% (Fig. S1, available at ). Freshly isolated naive T cells constitutively expressed high levels of EP2 and EP4 mRNA, whereas EP1 and EP3 mRNA expression was low or nonexistent (Fig. 1 A). Cell surface expression of EP2 and EP4 protein was confirmed by flow cytometric analysis (Fig. 1 B). Activation and culture of naive T cells led to a two- to threefold up-regulation of EP2 and EP4 transcripts (Fig. S2 A). This up-regulation was not affected by the addition of Th1-IL-12- or Th17-IL-23- and/or IL-1beta-polarizing culture conditions. EP1 and EP3 mRNA levels remained low after activation and culture under these same conditions. These results indicate that EP2 and EP4 constitute the major PGE2 receptors on naive and activated T cells.
###end p 11
###begin p 12
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGE2 up-regulates IL-23R and IL-1R1 expression on cultured human naive CD4<sup>+</sup> T cells.</bold>
###xml 115 118 115 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 134 137 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 390 391 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 605 606 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 610 611 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 752 758 752 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-1R1</italic>
###xml 924 925 924 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 929 930 929 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 157 162 <span type="species:ncbi:9606">human</span>
PGE2 up-regulates IL-23R and IL-1R1 expression on cultured human naive CD4+ T cells. (A) Real-time PCR analysis of EP1, EP2, EP3, and EP4 gene expression in human naive CD4+ T cells. Mean + SEM of eight donors. Relative amplification efficiencies of EP primer sets fell within standard Taqman assay specifications. (B) Isotype (gray) or EP2 and EP4 (black) surface staining. (C-G) Naive CD4+ T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence or absence of PGE2, dibutyryl-cAMP, or specific EP receptor agonists. (C-D) Flow cytometric quantification of IL-23R in CD3+ CD4+ T cells restimulated for 48 h. (D) Box and whiskers of eight independent experiments are shown. **, P < 0.01. (E) Real-time PCR analysis of IL-1R1 gene expression in T cells restimulated for 24 h. Results from six different donors are shown. *, P < 0.05. (F and G) Flow cytometric quantification of IL-23R in CD3+ CD4+ T cells restimulated for 48 h. Mean + SEM of four independent experiments.
###end p 12
###begin p 13
###xml 214 215 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 217 219 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 221 223 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 528 543 517 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, C and D</xref>
###xml 546 552 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-1R1</italic>
###xml 609 617 598 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 848 856 837 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 F</xref>
###xml 1087 1095 1076 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 G</xref>
###xml 63 68 <span type="species:ncbi:9606">human</span>
IL-23 and IL-1beta have been shown to drive the development of human Th17 cells, which are characterized by a specific signature cytokine profile consisting of IL-17, IL-17F, IL-22, CCL20/MIP3alpha, and IFN-gamma (9, 11, 12). To investigate a potential role of PGE2 in Th17 differentiation, we next examined the effects of PGE2 on the expression of IL-23 and IL-1 receptors. Interestingly, activation and culture of naive T cells in the presence of PGE2 resulted in a strong and reproducible up-regulation of IL-23R expression (Fig. 1, C and D). IL-1R1 gene expression was also increased in response to PGE2 (Fig. 1 E). Butaprost, an EP2 selective agonist, and misoprostol, a nonselective agonist with the highest affinity for EP4 and EP3, increased IL-23R expression comparable to PGE2. In contrast, the EP1/EP3 agonist sulprostone had no effect (Fig. 1 F), indicating that the effects of PGE2 on IL-23R expression were specifically mediated through EP2 and EP4 receptors. The addition of the intracellular cAMP analogue dibutyryl-cAMP mimicked the effect of PGE2 on IL-23R expression (Fig. 1 G), suggesting that the effect of PGE2 was dependent on cAMP formation. These results suggest a mechanism by which PGE2 could affect the Th17 pathway through up-regulation of IL-23 and IL-1 receptor expression.
###end p 13
###begin title 14
###xml 29 34 <span type="species:ncbi:9606">human</span>
PGE2 promotes development of human Th17 cells
###end title 14
###begin p 15
###xml 312 320 306 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 411 419 402 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 1042 1043 1015 1016 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1053 1054 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1064 1065 1033 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1518 1526 1477 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 1664 1672 1623 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 1972 1974 1931 1933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
As PGE2 enhanced both IL-23 and IL-1beta receptor expression from activated naive T cells, we determined whether PGE2 could modulate the effects of IL-1beta and IL-23 during the development of Th17 cells. Activation and culture of naive T cells with PGE2 alone slightly increased IL-17 production in few donors (Fig. 2 A). However, PGE2 significantly enhanced IL-17 production induced by IL-23 and/or IL-1beta (Fig. 2 A). The combination of IL-23, IL-1beta, and PGE2 (IL-23-IL-1beta-PGE2) did not lead to further increase in IL-17 production over that induced by PGE2 and IL-1beta. The addition of IL-23 to IL-23-IL-1beta-PGE2-treated cells compared with IL-23-IL-1beta cultures resulted in an enhanced phosphorylation of STAT3, which is in line with the up-regulated expression of IL-23R in the presence of PGE2 (Fig. S2 B), and indicates that the enhanced IL-23R expression is functional. The increase in IL-17 production induced by IL-1beta and IL-23 in response to PGE2 was dose dependent (Fig. S2 C). In addition, the proportion of IL-17+ and IL-17+/IFN-gamma+ producers was increased in IL-23-IL-1beta-PGE2 cultures compared with IL-23-IL-1beta-treated cells, whereas IFN-gamma single producers were present at similar levels (Fig. S2 D). Furthermore, the increased IL-17 production was more strongly controlled by EP2 than EP4 signaling because the EP2 agonist butaprost could mimic the effect of PGE2 to a similar extent, whereas misoprostol was not able to induce such a strong induction of IL-17 production (Fig. 2 B). The increase in IL-17 secretion mediated through activation of the cAMP pathway was consistent with the observed EP2 or EP4 signaling (Fig. 2 C). The effects of dibutyryl-cAMP on IL-17 production were consistent and dose dependent (Fig. S2 E). The differential increase of IL-17 production in response to EP2 or EP4 may be caused by the more robust stimulation of intracellular cAMP formation by EP2 compared with EP4, as previously reported (19).
###end p 15
###begin p 16
###xml 0 121 0 118 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGE2, together with IL-1&#946; and IL-23, enhances Th17 cell development predominantly via EP2 signaling and cAMP pathways.</bold>
###xml 137 138 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 405 414 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 122 127 <span type="species:ncbi:9606">Human</span>
PGE2, together with IL-1beta and IL-23, enhances Th17 cell development predominantly via EP2 signaling and cAMP pathways. Human naive CD4+ T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-23, IL-1beta, PGE2, dibutyryl-cAMP, and/or EP receptors agonists. (A-C) IL-17 production in cell-free supernatants of T cells restimulated for 48 h. (D) Real-time PCR of RORgammat gene expression in T cells after indicated time of culture. (E-G) IL-17F (E), CCL20 (F), and IL-22 (G) production in cell-free supernatants of T cells restimulated for 48 h. Data from six different donors are shown in A, E, F, and G; horizontal bars represent median values. Results in B show mean + SEM of three independent experiments. Data in C show mean + SEM of five independent experiments. Data in D are representative of two independent experiments. *, P < 0.05; **, P < 0.01.
###end p 16
###begin p 17
###xml 102 111 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 113 115 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 135 144 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 287 296 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 356 364 338 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 612 623 587 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 E, F</xref>
###xml 820 828 792 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 G</xref>
The development of Th17 cells is dependent on the induction of the Th17-specific transcription factor RORgammat (20). A time course of RORgammat expression during T cell polarization confirmed that after 11 d of culture, IL-23-IL-1beta-PGE2-derived Th17 cells expressed higher levels of RORgammat transcripts compared with IL-23-IL-1beta control cultures (Fig. 2 D), which is in agreement with the up-regulated IL-17 production by these cells. Th17 cells also produce IL-17F, IL-22, and CCL20/MIP3alpha. A similar profile of IL-23-IL-1beta-PGE2-dependent regulation was observed for IL-17F and CCL20 expression (Fig. 2 E, F). In contrast, IL-22 and IL-26 expression was decreased in the presence of PGE2 alone; however, their expression was not altered by the addition of PGE2 to cultures containing IL-23 and IL-1beta (Fig. 2 G and Fig. S2 F). These results indicated that although IL-22 and IL-26 are an integral part of Th17 biology, their expression is subject to multiple levels of regulation. All the observations on Th17 cytokine production were confirmed at the level of gene expression (Fig. S2 F). These results thus indicate that PGE2 can act directly on naive T cells and enhance Th17 development mainly through the EP2-cAMP pathway.
###end p 17
###begin title 18
PGE2 induces IL-17 production in T cell-APC co-cultures
###end title 18
###begin p 19
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 185 187 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 335 338 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 343 346 339 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 360 368 356 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 487 495 480 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 643 651 633 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1050 1058 1037 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 302 307 <span type="species:ncbi:9606">human</span>
PGE2 pretreatment of APCs promotes Th17 differentiation in mice by altering the IL-12/IL-23 balance (14-16, 21). In addition, PGE2 enhanced IFN-gamma and TLR7 induced IL-23 production (22). It was therefore of interest to determine the effects of PGE2 on T cells in the presence of APCs. Like T cells, human monocytes mainly expressed EP2 and EP4 transcripts (Fig. 3 A). Activation of monocytes through the TLR2 pathway by peptidoglycan resulted in the production of IL-23 and IL-1beta (Fig. 3 B). However, when monocytes were activated with PGE2 in the absence of TLR ligands or cytokines, we did not detect any IL-23 or IL-1beta production (Fig. 3 B). In line with these results, addition of PGE2 to co-culture of naive T cells with monocytes in the absence of exogenously added cytokines did not induce IL-17 production. Interestingly, in the presence of monocytes, the combination of IL-23 and IL-1beta failed to induce IL-17 production in most donors; however, addition of PGE2 overcame this suppressive effect and resulted in IL-17 production (Fig. 3 C). These results indicate that PGE2 was essential for IL-17 production induced by IL-23 and IL-1beta in this T cell-APC co-culture system.
###end p 19
###begin p 20
###xml 0 106 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGE2 is required for IL-23&#8211;IL-1&#946;&#8211;induced IL-17 production in a monocyte-naive T cell co-culture system.</bold>
###xml 137 140 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 142 145 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 147 150 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 156 159 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 189 190 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 244 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 459 460 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 179 184 <span type="species:ncbi:9606">human</span>
###xml 233 238 <span type="species:ncbi:9606">Human</span>
###xml 444 449 <span type="species:ncbi:9606">Human</span>
PGE2 is required for IL-23-IL-1beta-induced IL-17 production in a monocyte-naive T cell co-culture system. (A) Real-time PCR analysis of EP1, EP2, EP3, and EP4 gene expression in human CD14+ monocytes. Mean + SEM of four donors. (B) Human CD14+ monocytes were stimulated in the presence of peptidoglycan or PGE2 for 24 h. IL-1beta and IL-23 production was assessed in cell-free supernatants. Results from four independent donors are shown. (C) Human naive CD4+ T cells were co-cultured with monocytes (1:1), activated with anti-CD3 antibody, and cultured for 11 d in the presence of IL-23, IL-1beta, and/or PGE2. IL-17 production in cell-free supernatants of T cells restimulated for 48 h was measured by ELISA. Results from five independent donors are shown.
###end p 20
###begin title 21
PGE2 inhibits Th17 production of IL-10 and IFN-gamma predominantly through EP4 signaling
###end title 21
###begin p 22
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 258 266 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 465 473 462 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 587 595 584 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 762 770 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 873 875 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 152 157 <span type="species:ncbi:9606">human</span>
Recent evidence suggests that IL-10 restrains the pathogenicity of Th17 cells in mice (23, 24), prompting us to also examine the production of IL-10 in human Th17 cells. IL-23, but not IL-1beta, increased IL-10 production in activated naive T cell cultures (Fig. 4 A). IL-10 production remained below levels that were observed with IL-12 (unpublished data). Addition of PGE2 strongly suppressed the production of IL-10 in both control and Th17-inducing conditions (Fig. 4 A). This effect was mainly mediated through EP4 signaling as shown by the addition of the EP4 agonist misoprostol (Fig. 4 B). Interestingly, although dibutyryl-cAMP inhibited IL-10 production in control cultures, it failed to down-regulate IL-10 production in IL-23-IL-1beta-treated cells (Fig. 4 C), suggesting that additional signaling pathways are involved in response to PGE2 and EP4 stimulation (19). These results further corroborate the finding that down-regulation of the antiinflammatory IL-10 pathway by PGE2 might further exacerbate Th17-mediated inflammation.
###end p 22
###begin p 23
###xml 0 95 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGE2 inhibits IL-10 and IFN-&#947; production predominantly via EP4 signaling and cAMP pathways.</bold>
###xml 111 112 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 465 470 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T-bet</italic>
###xml 96 101 <span type="species:ncbi:9606">Human</span>
PGE2 inhibits IL-10 and IFN-gamma production predominantly via EP4 signaling and cAMP pathways. Human naive CD4+ T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-23, IL-1beta, PGE2, dibutyryl-cAMP, and/or EP receptor agonists. (A-C) IL-10 production in cell-free supernatants of T cells restimulated for 48 h. (D-F) IFN-gamma production in cell-free supernatants of T cells restimulated for 48 h. (G) Real-time PCR of T-bet mRNA expression in T cells after 11 d of culture. Data from six different donors are shown in A and D; horizontal bars represent median values. Results in B and E show mean + SEM of three independent experiments. Data in C and F show mean + SEM of five independent experiments. Data in G are representative of two independent experiments. *, P < 0.05; ***, P < 0.001.
###end p 23
###begin p 24
###xml 115 123 111 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 168 170 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 171 173 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 255 257 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 377 378 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 491 499 469 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 682 690 656 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 E</xref>
###xml 723 731 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 F</xref>
###xml 1011 1016 978 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T-bet</italic>
###xml 1108 1113 1072 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T-bet</italic>
###xml 1187 1195 1148 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 G</xref>
###xml 268 273 <span type="species:ncbi:9606">human</span>
PGE2 suppressed IFN-gamma production from activated naive T cells cultured in the absence of additional cytokines (Fig. 4 D), in accordance with the established dogma (25-27). We previously reported that IL-23 enhanced IFN-gamma production by PHA blasts (28) and that human Th17 cells, differentiated in the presence of either IL-1beta or IL-23, are able to produce IFN-gamma (9). The production of IFN-gamma by Th17 cells differentiated by IL-1beta or IL-23 was strongly inhibited by PGE2 (Fig. 4 D). The inhibitory effect of PGE2 on IFN-gamma production was predominantly mediated through EP4 signaling because it could be mimicked by the addition of the EP4 agonist misoprostol (Fig. 4 E) and through elevation of cAMP (Fig. 4 F). However, when Th17 cells were generated by the combination of IL-1beta and IL-23, PGE2 was not able to inhibit IFN-gamma secretion, indicating that PGE2 could not effectively interfere with the efficacy of the combined signal transduction pathways. Accordingly, PGE2 inhibited T-bet mRNA expression in activated T cells differentiated with either IL-1beta or IL-23, whereas T-bet levels were only slightly reduced in IL-23-IL-1beta-PGE2-cultured cells (Fig. 4 G). These results indicate that the ability of PGE2 to inhibit IFN-gamma production is dependent on the maturation state of the T cells and cytokine milieu. Overall, these data indicate that PGE2 modulates the Th17 phenotype to a high IL-17-, IL-17F-, CCL20-, low IFN-gamma-, low IL-10-producing cell that could be more pathogenic.
###end p 24
###begin title 25
PGE2 enhances maturation of developing Th17 cells
###end title 25
###begin p 26
###xml 238 239 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 241 243 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 432 447 423 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A and B</xref>
###xml 480 481 471 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 485 486 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 495 496 486 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 502 503 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 511 526 502 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, C and D</xref>
###xml 614 615 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 637 638 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 772 780 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 858 859 842 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1019 1020 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1040 1048 1021 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 F</xref>
###xml 1061 1062 1042 1043 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1072 1073 1049 1050 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1083 1084 1060 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1094 1095 1067 1068 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1151 1152 1124 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1188 1189 1161 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1256 1264 1225 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 G</xref>
###xml 1275 1276 1244 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1378 1384 1347 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-23R</italic>
###xml 1389 1398 1358 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 1412 1427 1377 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, H and I</xref>
###xml 1480 1481 1445 1446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1561 1576 1523 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, A and B</xref>
###xml 1595 1596 1557 1558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1714 1722 1673 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 1763 1764 1722 1723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1771 1772 1730 1731 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1782 1783 1737 1738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1802 1803 1753 1754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1868 1876 1816 1824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 212 217 <span type="species:ncbi:9606">human</span>
In addition to its effects on cytokine and cytokine receptor expression, the combined activity of PGE2, IL-1beta, and IL-23 led to an enhanced maturation of developing Th17 cells. Memory Th17 cells isolated from human blood express CCR6 (8, 18), the receptor for CCL20 and beta-defensins. We observed that only the combined presence of IL-23, IL-1beta, and PGE2 led to an enhanced up-regulation of CCR6 expression in naive T cells (Fig. 5, A and B), as well as an increase of CCR6+CCR4+ and CCR6+IL-23R+ cells (Fig. 5, C and D). CCR6 expressed by IL-23-, IL-1beta-, and PGE2-treated T cells was functional, as CCR6+ T cells, but not CCR6- T cells, had chemotactic activities in response to its ligand CCL20. Both T cell populations migrated equally well toward SDF1alpha (Fig. 5 E), a ligand of CXCR4 that is expressed on T cells. Reactivation of sorted CCR6+ T cells isolated from IL-23-IL-1beta-PGE2-driven Th17 cells revealed that >50% were IL-17-producing cells, whereas few IL-17 producers were present in the CCR6- T cell population (Fig. 5 F). Both IL-17+ IFN-gamma+ and IL-17+ IFN-gamma- T cells were present at similar percentages in the CCR6+ T cell population, whereas the CCR6- T cell fraction contained predominantly IFN-gamma only producers (Fig. 5 G). The CCR6+ T cells also expressed higher levels of the other Th17 cytokines IL-17F, IL-22, CCL20, as well as of IL-23R and RORgammat transcripts (Fig. 5, H and I). A similar Th17 profile was observed in sorted CCR6+ T cells isolated from IL-23-IL-1beta-driven Th17 cells in the absence of PGE2 (Fig. 6, A and B). Strikingly, CCR6+ T cells from IL-23-IL-1beta-treated cells in the presence of PGE2 expressed higher levels of all these Th17 markers (Fig. 6 B). Interestingly, the proportion of IL-17+, IL-17+/IFN-gamma+, but not IFN-gamma+-producing cells, was increased in IL-23-IL-1beta-PGE2 cultures (Fig. 6 A), demonstrating that PGE2 not only quantitatively enhanced the number of IL-17 producers but also increased their intrinsic capacity to produce IL-17. Collectively, these data indicate that PGE2 also enhanced maturation of Th17 cells.
###end p 26
###begin p 27
###xml 0 113 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR6 expression defines Th17 cytokine producers and is up-regulated in the presence of IL-1&#946;, IL-23, and PGE2.</bold>
###xml 129 130 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 303 304 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 309 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 446 447 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 457 458 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 462 463 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 476 477 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 483 484 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 495 496 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 500 501 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 615 616 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 620 621 614 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 629 630 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 634 635 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1267 1268 1247 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1272 1273 1252 1253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1281 1282 1261 1262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1286 1287 1266 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1711 1717 1687 1693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-23R</italic>
###xml 1722 1731 1698 1703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 114 119 <span type="species:ncbi:9606">Human</span>
CCR6 expression defines Th17 cytokine producers and is up-regulated in the presence of IL-1beta, IL-23, and PGE2. Human naive CD4+ T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-23, IL-1beta, and/or PGE2. (A) Flow cytometric quantification of CCR6 in CD3+ CD4+ T cells restimulated for 48 h. Results are representative of three independent experiments. (B-D) Flow cytometric quantification of CCR6+ (B), CCR6+CCR4+ (C), or CCR6+IL-23R+ (D) in CD3+ CD4+ T cells restimulated for 48 h. *, P < 0.05. Results represent mean + SEM of nine independent experiments. (E) CD4+CCR6+ and CD4+CCR6- T cells from IL-1beta, IL-23, and PGE2-treated T cells were sorted and added to inserts that were placed in wells containing CCL20 or SDF-1alpha, forming an upper and lower chamber separated by a membrane bearing 5-microm pores. Responding cells that migrated to the lower chamber were harvested and counted by flow cytometry. Results represent mean + SEM of two independent donors and are expressed as the percentage of migration compared with the 100% migration control. (F-I) Naive T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d in the presence of IL-1beta, IL-23, and/or PGE2. After reactivation, CD4+CCR6+ and CD4+CCR6- T cells were sorted and cultured for 7 d in the presence of IL-2. (F and G) Intracellular IL-17 and IFN-gamma staining after stimulation with PMA/ionomycin. Results from six independent donors are shown in F. *, P < 0.05. Data in G are representative of six independent experiments. (H) Production of IL-17, IL-17F, IL-22, and CCL20 in cell-free supernatants of T cells restimulated for 24 h. (I) Real-time PCR analysis of IL-23R and RORgammat gene expression in T cells restimulated 24 h. Results in H and I are representative of four independent experiments.
###end p 27
###begin p 28
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGE2 enhances maturation of Th17 cells.</bold>
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 213 214 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 218 219 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 227 228 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 232 233 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 483 488 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17</italic>
###xml 490 496 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-17F</italic>
###xml 498 503 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-22</italic>
###xml 505 510 498 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCL20</italic>
###xml 511 518 504 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> IL-23R</italic>
###xml 523 533 516 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> ROR&#947;t</italic>
###xml 40 45 <span type="species:ncbi:9606">Human</span>
PGE2 enhances maturation of Th17 cells. Human naive CD4+ T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 11 d with IL-1beta and -23, in the presence or absence of PGE2. After reactivation, CD4+CCR6+ and CD4+CCR6- T cells were sorted from both cultures and cultured for 7 d in the presence of IL-2. (A) Intracellular IL-17 and IFN-gamma staining after stimulation with PMA/Ionomycin. Results from three independent donors are shown. (B) Real-time PCR analysis of IL-17, IL-17F, IL-22, CCL20, IL-23R, and RORgammat in T cells restimulated for 24 h. Results from five donors are shown; horizontal bars represent median values.
###end p 28
###begin title 29
PGE2 regulates memory Th17 cell function
###end title 29
###begin p 30
###xml 252 253 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 259 260 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 391 394 391 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 404 412 404 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 602 610 602 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 665 671 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-1R1</italic>
###xml 700 708 700 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 966 968 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 1061 1069 1055 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 1270 1279 1258 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 1281 1289 1265 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 E</xref>
###xml 1330 1339 1314 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 1432 1434 1409 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 1608 1613 1581 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T-bet</italic>
###xml 1718 1729 1688 1699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, F&#8211;H</xref>
###xml 1782 1787 1748 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T-bet</italic>
###xml 1848 1859 1811 1822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, F&#8211;H</xref>
As activated/memory T cells constitute a major cell population found in inflamed tissue, we next assessed whether PGE2 could affect the function of mature Th17 cells in short-term cultures. We previously identified in situ Th17 cells as part of the CD4+CD45RO+ memory T cell subset that expresses the IL-23R in PBMCs of normal donors (9). Like naive T cells, memory T cells mainly expressed EP2 and EP4 (Fig. 7 A) and could respond to PGE2. Consistent with their Th17 memory phenotype, PGE2 stimulation did not further enhance the percentage of IL-23R-positive cells or the level of IL-23R expression (Fig. 7 B). However, PGE2 did up-regulate the expression of the IL-1R1 mRNA on the memory T cells (Fig. 7 C), and also modulated cytokine production and transcription factor profiles. The activation of memory T cells with IL-1beta enhanced IL-17 production, and the combination of both IL-1beta and IL-23 led to a higher IL-17 up-regulation, as recently described (29). The presence of PGE2 alone or with IL-23 did not enhance IL-17 production in most donors (Fig. 7 D). However, PGE2 enhanced IL-17 production induced by IL-1beta and the combination of PGE2, IL-1beta, and IL-23 induced an even stronger IL-17 up-regulation that correlated with enhanced expression of RORgammat (Fig. 7 E). Interestingly even PGE2 alone induced RORgammat expression, but not IL-17 production. Similar results were recently described for TGF-beta (30), and are consistent with the requirements for additional (transcription) factors to fully induce IL-17 production. Similar to naive T cells, PGE2 down-regulated IFN-gamma, T-bet, and IL-10 expression by activated memory T cells cultured without cytokines or with IL-1beta or IL-23 (Fig. 4, F-H). Furthermore, PGE2 inhibited IFN-gamma, IL-10, and T-bet expression even in the presence of both IL-1beta and IL-23 (Fig. 4, F-H). Thus PGE2 will not only affect the phenotype and function of differentiating Th17 cells but also the function of mature effector Th17 cells.
###end p 30
###begin p 31
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGE2 modulates memory Th17 functions.</bold>
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 77 80 77 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 86 89 86 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 180 181 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 451 457 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-1R1</italic>
###xml 590 599 587 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ROR&#947;t</italic>
###xml 690 695 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T-bet</italic>
###xml 109 114 <span type="species:ncbi:9606">human</span>
PGE2 modulates memory Th17 functions.(A) Real-time PCR analysis of EP1, EP2, EP3, and EP4 gene expression in human memory CD4+ T cells. Mean + SEM of three donors. (B-H) Memory CD4+ T cells were activated with anti-CD3/CD28/CD2 beads and cultured for 3 d in the presence or absence of IL-23, IL-1beta, and/or PGE2. (B) Flow cytometric quantification of IL-23R. Box and whiskers of five independent experiments are shown. (C) Real-time PCR analysis of IL-1R1 gene expression. Results from four different donors are shown. (D) IL-17 production in cell-free supernatants. (E) Real-time PCR of RORgammat gene expression. (F) IFN-gamma production in cell-free supernatants. (G) Real-time PCR of T-bet gene expression. (H) IL-10 production in cell-free supernatants. Data from four (E and G) or nine (D, F, and H) independent donors are shown; horizontal bars represent median values. *, P <0.05.
###end p 31
###begin title 32
###xml 15 21 <span type="species:ncbi:10090">murine</span>
PGE2 regulates murine Th17 function
###end title 32
###begin p 33
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 173 176 173 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 192 195 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 200 203 200 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 240 248 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 A</xref>
###xml 366 368 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 369 371 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 484 486 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 488 490 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 526 527 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 531 533 522 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 538 539 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 933 941 915 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 B</xref>
###xml 1007 1008 989 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1012 1014 994 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 1019 1021 1001 1003 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 1038 1046 1020 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 B</xref>
###xml 1425 1433 1401 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 C</xref>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 118 124 <span type="species:ncbi:10090">murine</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 1242 1247 <span type="species:ncbi:10090">mouse</span>
###xml 1522 1527 <span type="species:ncbi:9606">human</span>
###xml 1532 1538 <span type="species:ncbi:10090">murine</span>
We also assessed whether PGE2 could directly affect IL-17 production from mouse CD4+ T cells. Similar to human cells, murine naive and memory CD4+ T cells expressed EP2 and EP4 genes, whereas EP1 and EP3 mRNA transcripts were not detected (Fig. 8 A). The combination of TGF-beta and IL-6 (TGF-beta-IL-6) is crucial for the initial development of Th17 cells in mice (31-33), whereas IL-1beta and IL-23 are important for the maturation, expansion, and effector function of this subset (24, 34). Stimulation of purified naive CD4+CD44loCD62L+ T cells with anti-CD3 and -CD28 antibodies in the presence of TGF-beta-IL-6 led to IL-17 production, as previously described. Restimulation of these newly activated T cells in the presence of IL-1beta or IL-23 maintained IL-17 production. Furthermore, addition of PGE2 during this restimulation step greatly enhanced IL-17 production, particularly in combination with both IL-1beta and IL-23 (Fig. 8 B). A similar profile was observed with stimulation of purified CD4+CD44hiCD62Llo memory T cells (Fig. 8 B). Once again, it is the combination of PGE2, IL-1beta, and IL-23 that induced the highest level of IL-17 production. The effect of PGE2 on IL-10 production by naive and memory T cells in several mouse strains was also examined. As expected, activation of these cells in the presence of TGF-beta-IL-6 induced the production of IL-10, which was inhibited by the addition of PGE2 (Fig. 8 C). These results suggest that the direct effects of PGE2 on Th17 cells are comparable in human and murine biology.
###end p 33
###begin p 34
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PEG2 regulates murine Th17 cell functions.</bold>
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP1</italic>
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP2</italic>
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP3</italic>
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EP4</italic>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 282 284 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 289 291 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 384 386 384 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 391 393 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 457 459 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 464 466 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 544 545 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 559 561 559 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 565 567 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 809 810 806 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 824 826 821 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 830 832 827 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 1149 1154 1146 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 1192 1193 1189 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1467 1468 1464 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1472 1474 1469 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 1479 1481 1476 1478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 1579 1580 1576 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1584 1586 1581 1583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 1591 1593 1588 1590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 1662 1663 1659 1660 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1667 1669 1664 1666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 1674 1676 1671 1673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 15 21 <span type="species:ncbi:10090">murine</span>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
###xml 215 218 <span type="species:ncbi:31658">CFA</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 495 510 <span type="species:ncbi:10090">transgenic mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 1183 1188 <span type="species:ncbi:10090">mouse</span>
###xml 1274 1277 <span type="species:ncbi:31658">CFA</span>
###xml 1289 1293 <span type="species:ncbi:10090">mice</span>
###xml 1521 1525 <span type="species:ncbi:10090">mice</span>
###xml 1607 1611 <span type="species:ncbi:10090">mice</span>
###xml 1705 1720 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1797 1802 <span type="species:ncbi:10090">mouse</span>
PEG2 regulates murine Th17 cell functions. (A) Real-time PCR analysis of EP1, EP2, EP3, and EP4 gene expression in purified mouse CD4+ T cells. Closed triangle symbols represent T cells from draining lymph nodes of CFA-primed SJL mice. Open triangle symbols represent naive CD4+CD44loCD62Lhi from lymph nodes and spleen of C57BL/6 mice. Closed circle symbols represent memory CD4+CD44hiCD62Llo from C57BL/6 mice. Open circle symbols represent naive CD4+CD44loCD62Lhi from BALB/c DO11.10 OVA-TCR transgenic mice. (B, top) FACS-purified naive CD4+ T cells (CD44loCD25lo) from SJL mice were activated with anti-CD3/CD28 beads in the presence of TGF-beta and IL-6 for 3 d. Cells were then restimulated for 5 d in the presence of the indicated combinations of cytokines with or without PGE2. (B, bottom) Memory CD4+ T cells (CD44hiCD25lo) were activated with anti-CD3/CD28 beads in the presence of cytokines with or without PGE2 for 4 d. IL-17 production in cell-free supernatants was assessed by ELISA and expressed as values normalized to the final number of cells per well. Results are representative of two experiments. (C) Real-time PCR analysis of IL-10 gene expression in purified mouse CD4+ T cells. Closed triangle symbols represent T cells from draining lymph nodes of CFA-primed SJL mice. Cells were cultured for 12 h with indicated cytokines with or without PGE2. Cells cultured for 2 d showed similar results (not depicted). Open triangles represent naive CD4+CD44loCD62Lhi from lymph nodes and spleen of C57BL/6 mice cultured for 1 d. Filled circles represent memory CD4+CD44hiCD62Llo from C57BL/6 mice cultured for 1 d. Open circles represent naive CD4+CD44loCD62Lhi from BALB/c DO11.10 OVA-TCR transgenic mice cultured for 2 d. SJL and BALB/c data are representative of two experiments/mouse strain, whereas results from naive and memory C57BL/6 cells are from one experiment.
###end p 34
###begin title 35
DISCUSSION
###end title 35
###begin p 36
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 696 697 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 992 998 992 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9</xref>
###xml 1521 1522 1517 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 1524 1526 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1528 1530 1524 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 1602 1603 1598 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2928 2934 2907 2913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Fig. 9</xref>
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 715 720 <span type="species:ncbi:9606">human</span>
###xml 924 929 <span type="species:ncbi:9606">human</span>
###xml 3014 3019 <span type="species:ncbi:9606">human</span>
###xml 3023 3029 <span type="species:ncbi:10090">murine</span>
Cyclooxygenase 2 (COX2) inhibitors inhibit prostaglandin synthesis, including PGE2, and are used in human to treat chronic inflammatory diseases such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis (35, 36). In addition, COX2 inhibitors have been shown to reduce the severity of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice (37, 38). These autoimmune disease models are associated with exacerbated Th17 responses, which are driven by the presence of proinflammatory cytokines such as IL-1 and IL-23 (13) In this context, Chizzolini et al. recently reported that another inflammatory mediator, PGE2, enhanced IL-17 production from memory CD4+ T cells in total human PBMC cultures (17). Here, we specifically assessed the PGE2-mediated effects on T cell development and function. We showed that PGE2 signals via EP2 and EP4 receptors and the cAMP-PKA pathway to promote human naive T cell differentiation to Th17 cells (proposed model in Fig. 9). PGE2 up-regulated the expression of IL-23R and IL-1R on differentiating naive T cells and, in combination with Th17-driving cytokines, enhanced STAT3 phosphorylation and induced a qualitative and quantitative shift in function and phenotype toward a strong proinflammatory/pathogenic Th17 cell. PGE2 enhanced the percentage of CCR6-positive, in vitro-matured Th17 cells that expressed IL-17A, IL-22, IL-17F, CCL20, RORgammat, and IL-23R, and it significantly up-regulated these functional markers of the Th17 phenotype (9, 11, 12). This enhanced Th17 functionality was also observed when mature CD45RO+ memory T cell populations were activated by IL-1beta and PGE2. Although previous studies have reported that PGE2 has antiproliferative effects on T cells, we did not observe a strong inhibition of proliferation when naive T cells were cultured in the presence of IL-23 and IL-1beta (unpublished data). There are two plausible explanations that may reconcile PGE2's apparent antiproliferative effect and our pro-Th17 cell development findings: (a) in the presence of IL-1beta and IL-23, PGE2 may favor the development and/or expansion of Th17 cells, while down-regulating proliferation of non-Th17 cells; (b) PGE2 may act on "non-Th17 cells" and convert them into IL-17 producers, while suppressing overall T cell proliferative responses, resulting in an "apparent" increase in the number of Th17 cells. Furthermore, in addition to these direct effects of PGE2 on T cells, PGE2 was also essential for the induction of IL-17 production from naive T cells in an APC-dependent manner. We demonstrate that PGE2 inhibits IFN-gamma and IL-10 production by Th17 cells and thus regulates their pathogenic potential. The opposing effects of PGE2 on increased IL-17 production and reduced IFN-gamma and IL-10 production are mediated by differential signaling through EP2 and EP4 receptors, which is unique in PGE2 signal transduction (Fig. 9). Finally, we show that the PGE2 effects on Th17 function can be extended from human to murine biology. Overall, we show that the proinflammatory activity of PGE2 is mediated through the IL-23-Th17 pathway.
###end p 36
###begin p 37
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Proposed model for PGE2 effects during Th17 cell development.</bold>
Proposed model for PGE2 effects during Th17 cell development. (A) Binding of PGE2 to EP2 and EP4 enhances intracellular cAMP formation and signaling, leading to up-regulation of IL-23R and IL-1R1 expression, as well as inhibition of the expression of T-bet and production of IFN-gamma. PGE2 binding to EP4 also induces concomitant signaling pathways independent of cAMP, such as PI3K or ERK, leading to inhibition of IL-10 production. (B) The presence of IL-23, IL-1beta, and PGE2 leads to an up-regulation of RORgammat, IL-17, and CCR6 expression and inhibition of IL-10. Gs, stimulatory guanine nucleotide binding protein.
###end p 37
###begin p 38
###xml 187 188 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 1171 1173 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 1853 1855 1846 1848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 1857 1859 1850 1852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">41</xref>
Our results provide new mechanistic insights regarding PGE2-mediated signaling in Th17 cells. We show that EP2 and EP4, but not EP1 or EP3, are the receptors mediating PGE2 effects on CD4+ T cells. In addition, PGE2 activities are likely mediated through the cAMP-PKA pathway, as the effects of PGE2 can be mimicked in the presence of the cAMP analogue dibutyryl cAMP. These findings are in line with the previously reported induction of the cAMP-PKA pathway by EP2 and EP4 (19, 39). Furthermore, we show that stimulatory and inhibitory activities of PGE2 on cytokine production seem to be mediated by specific PGE2 receptors, as enhanced IL-17 production is preferentially mediated by EP2 signaling, whereas inhibition of IL-10 and IFN-gamma production occurs mainly through EP4 signaling. In addition, the inhibition of IL-10 production induced by cAMP was not observed in the presence of IL-1beta and IL-23, suggesting the induction of additional signaling pathway(s) in response to EP4 stimulation. It has been shown that EP4, but not EP2, can also induce a concomitant activation of phosphatidyl inositol 3 kinase and extracellular signal-regulated kinase pathways (39). However, addition of phosphatidyl inositol 3 kinase and MAP kinase inhibitors to our cultures completely inhibited all cytokine production by T cells (unpublished data), so it was not possible to formally test this hypothesis. It is of interest to note that PGE2 and the cAMP pathway have been shown to up-regulate IL-10 expression in monocytic cells through a cAMP-responsive element (CRE) in the IL-10 promoter. However, the cAMP-induced PKA-dependent phosphorylation of the CRE-binding protein 1 does not seem to have an important regulatory role in T cells, which is also reflected by their lack of responsiveness to catecholamine-induced, cAMP-dependent IL-10 production (40, 41).
###end p 38
###begin p 39
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 805 806 802 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1091 1092 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1189 1190 1180 1181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1193 1194 1184 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1228 1230 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 1277 1278 1268 1269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1363 1365 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 1033 1038 <span type="species:ncbi:9606">human</span>
Human CD4+ memory T cells producing IL-17 were first identified from peripheral blood or gut of healthy and Crohn's patients (8), and increasing efforts have been made to characterize this cell subset. Two groups independently identified CCR6 as a chemokine receptor selectively expressed on Th17 cells (8, 18). CCR6 is involved in the recruitment of pathogenic T cells in multiple sclerosis, rheumatoid arthritis, Crohn's disease, and psoriasis (8, 42-44), and Th17 cells are increasingly recognized as crucial mediators of those diseases (7, 9, 10, 45, 46). Therefore, the up-regulated CCR6 expression in IL-23-IL-1beta-PGE2-driven Th17 cells is consistent with the generation of cells bearing the phenotype of pathogenic effector Th17 cells. In addition, the higher expression of Th17 cytokines in CCR6+ cells isolated from cells treated with a combination of IL-23, IL-1beta, and PGE2 compared with IL-23-IL-1beta-treated cells suggest a stronger maturation of Th17 cells in the presence of PGE2. It has been recently shown that human IL-17-producing cells are contained within the CD161+ fraction of circulating or tissue-infiltrating T cells and that these cells originate from CD161+CD4+ T cells of umbilical cord blood (47). Additional data also suggest that such CD161+ Th17 cells are crucial mediators of intestinal inflammation during Crohn's disease (48).
###end p 39
###begin p 40
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">49</xref>
###xml 460 462 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 411 416 <span type="species:ncbi:10090">mouse</span>
###xml 489 494 <span type="species:ncbi:9606">human</span>
IL-10 was originally described as an immunosuppressive cytokine produced by Th2 cells. However, it is now recognized that all T cell subsets can produce this cytokine as a feedback response to suppress immune pathologies (23, 49). Indeed, we have previously shown that TGF-beta induced IL-10 production even in the presence of IL-6 and/or IL-23, and that IL-10 can restrain the pathogenicity of Th17 cells in a mouse model of CNS autoimmune encephalomyelitis (24). As shown in this study, human Th17 cells stimulated in the presence of IL-1beta and/or IL-23 produced IL-10. Thus, the ability of PGE2 to strongly inhibit IL-10 production is crucial to enhancement of Th17-mediated inflammation and pathogenicity.
###end p 40
###begin p 41
###xml 111 113 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 115 117 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 119 121 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">50</xref>
###xml 369 370 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 380 381 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 399 400 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 410 411 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 574 576 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 726 727 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 716 724 <span type="species:ncbi:9606">patients</span>
PGE2 is also an important regulator of Th1 cells, particularly through the inhibition of IFN-gamma production (25, 26, 50). We show here that PGE2 also inhibited IFN-gamma production by Th17 cells generated in the presence of IL-1beta or IL-23; however, the signaling pathways induced by both cytokines prevented this inhibition and led to the development of both IL-17+/IFN-gamma-, as well as IL-17+/IFN-gamma+ producers. These results are in accordance with the phenotype of Th17 cells observed by Chizzolini et al. when culturing PBMCs in the presence of IL-23 and PGE2 (17). Interestingly, ex vivo Th17 cells producing IL-17 alone or both IL-17 and IFN-gamma have been identified in the blood and gut of Crohn's patients (8). Our results support the idea that the presence of IL-23, IL-1beta, and PGE2 would lead to the development of Th17 cells bearing a phenotype/cytokine profile close to that found during disease.
###end p 41
###begin p 42
###xml 268 270 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 272 274 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 276 278 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 44 50 <span type="species:ncbi:10090">murine</span>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
Our results show that PGE2 directly acts on murine Th17 cells to enhance IL-17 production. This extends previous studies demonstrating that in the mouse system, PGE2's pro-Th17 effects were mediated through enhanced DC and macrophage production of IL-23 and IL-1beta (14, 15, 21). Hence, the mechanisms of PGE2-mediated expansion of pathogenic Th17 cells are likely through both T cell-dependent and myeloid cell-dependent pathways.
###end p 42
###begin p 43
###xml 202 203 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 493 494 487 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 611 612 602 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 875 876 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1349 1351 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
###xml 289 295 <span type="species:ncbi:10090">murine</span>
###xml 343 349 <span type="species:ncbi:10090">murine</span>
###xml 712 717 <span type="species:ncbi:9606">human</span>
###xml 804 809 <span type="species:ncbi:9606">human</span>
###xml 1022 1028 <span type="species:ncbi:10090">murine</span>
###xml 1080 1085 <span type="species:ncbi:9606">human</span>
###xml 1211 1216 <span type="species:ncbi:9606">human</span>
In the mouse culture system, it is well established that the combination of TGF-beta and IL-6 is necessary and sufficient to promote both in vitro (and likely in vivo) development of IL-17-producing CD4+ T cells. It is important to note that IL-6 is a major driver of IL-1R1 and IL-23R in murine T cells. Our assessment of PGE2's influence on murine T cell differentiation toward Th17 cells indicated that PGE2 cannot replace TGF-beta and/or IL-6 for induction of Th17 cells in a 3-d naive CD4+ T cell assay (unpublished data). This was not unexpected, as TGF-beta/IL-6 can promote 30-70% of IL-17-producing CD4+ T cells in our culture system. PGE2 has more profound effects on differentiating Th17 cells in our human culture system. Although we did not observe a TGF-beta/IL-6-dependent effect on naive human T cells, we found that PGE2 induced IL-1R and IL-23R in naive CD4+ T cells, which enhanced the development of Th17 cells induced by IL-23 and IL-1beta. Although TGF-beta is clearly required for the generation of murine Th17 cells, its role during the development of the human counterpart is still controversial. In this regard, Santarlasci et al. recently suggested that TGF-beta was not critical for human Th17 cell development; instead, TGF-beta would indirectly favor expansion of Th17 cells through inhibition of Th1 cell development (51).
###end p 43
###begin p 44
In conclusion, our study highlights the role of the inflammatory microenvironment as a critical factor in Th17 development and regulation. Our findings also shed light on a paradox where the important role of PGE2 in mediating inflammation remained controversial in respect to its effects on T helper cell function and cytokine production.
###end p 44
###begin title 45
MATERIALS AND METHODS
###end title 45
###begin title 46

###end title 46
###begin title 47
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cell cultures.
###end title 47
###begin p 48
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 390 391 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 473 474 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:9606">Human</span>
###xml 543 548 <span type="species:ncbi:9606">human</span>
Buffy coats were obtained from normal healthy human volunteers participating in the Stanford Medical School Blood Center blood donation program in accordance with the Declaration of Helsinki. Human protocols were approved by the Schering Plough Institutional Biosafety Committee. CD14+ monocytes were isolated from normal peripheral blood using CD14 microbeads (Miltenyi Biotech). Naive CD4+CD45RO- T cells were isolated and cultured as previously described (9). Memory CD4+CD45RA- T cells were isolated using the memory T cell isolation kit, human (Miltenyi Biotech), according to the manufacturer's instructions. T cells were activated in the presence of beads coated with anti-CD3/CD28/CD2 antibodies (1 bead:10 cells). For co-culture experiments, monocytes and naive T cells were cultured at a 1:1 ratio in the presence of 0.2 microg/ml anti-CD3 mAb (Spv-T3b; DNAX). Where indicated, 50 ng/ml hIL-23 (DNAX), 50 ng/ml hIL-1beta (R&D Systems), 10 microM PGE2 (Sigma-Aldrich), 10 microM butaprost (EP2 agonist), 35 microM misoprostol (EP4,EP3>EP1>EP2 agonist), 10 microM sulprostone (EP1/EP3 agonist; Cayman Chemical), or 100 microM of dibutyryl-cAMP (Alexis Biochemicals) were added.
###end p 48
###begin title 49
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse cell cultures.
###end title 49
###begin p 50
###xml 458 459 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 569 570 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 574 576 574 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 580 582 580 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 597 598 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 602 604 602 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 608 610 608 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 360 375 <span type="species:ncbi:10090">transgenic mice</span>
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
Handling of mice and experimental procedures were approved by and conducted in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines of the Schering-Plough Biopharma Institutional Animal Care and Use Committee. Lymph nodes and spleen cells from naive SJL/J, C57BL/6 (JAX Laboratories), or BALB/c DO11.10 OVA TCR transgenic mice (maintained at the Schering-Plough Biopharma mouse facility) were enriched for CD4+ cells using magnetic purification (Miltenyi Biotech), according to the manufacturer's instructions. Naive CD4+CD44loCD25lo and memory CD4+CD44hiCD25lo T cells were then purified by FACS. Memory cells were stimulated for 4 d with CD3/CD28 T cell expander beads (Dynal) in the presence of different cytokines (5 ng/ml IL-1beta; 20 ng/ml IL-23) and/or 10 microM PGE2. Cells were then counted using a Vicell counter and supernatants were analyzed by ELISA. Naive cells were cultured for 3 d with CD3/CD28 T cell expander beads (Dynal) and 10 ng/ml TGF-beta and 100 ng/ml IL-6 (R&D Systems). Cells were washed and stimulated for an additional 5 d with different cytokines before cell number was assessed and supernatant cytokine was analyzed by ELISA. Cytokine levels are expressed as values normalized to the final number of cells per well.
###end p 50
###begin title 51
Chemotaxis assays.
###end title 51
###begin p 52
###xml 86 88 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 90 92 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">53</xref>
Migration assays were performed in 5-microM pore transwells, as previously described (52, 53), using 100 nM CCL20 or 50 nM SDF1alpha (R&D Systems). The migration was carried out for 2 h at 37degreesC, and then a known number of counting beads was added to each well. Beads and cells were easily distinguishable by flow cytometry when plotting side scatter versus forward scatter, allowing the determination of the cell/bead ratio. The cell/bead ratio obtained from cells added directly to the wells was considered as 100% migration.
###end p 52
###begin title 53
Cell sorting.
###end title 53
###begin p 54
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
CD4+CCR6+ and CD4+CCR6- cell subsets were purified by cell sorting using anti-CCR6 and -CD4 antibodies (BD). Cell sorting was done with a FACSAria instrument (BD).
###end p 54
###begin title 55
Cell surface receptor and intracellular cytokine staining.
###end title 55
###begin p 56
For analysis of cell surface proteins, cells were stained with anti-CD4, -CD3, -CD45RA, -CCR6, -CCR4 (BD), -EP2, -EP4 (Cayman Chemical), and/or -IL-23R (BAF1400; R&D Systems) antibodies. For intracellular staining, cells were stimulated for 5 h with PMA, ionomycin (Sigma-Aldrich), and GolgiStop (BD), and permeabilized and stained with anti-IL-17 (eBioscience) and anti-IFN-gamma (BD) antibodies using the Cytofix/Cytoperm Plus kit (BD). For STAT3 phosphorylation analysis, cells were stimulated for 15 min in the presence of IL-23. Cells were fixed, permeabilized, and stained with anti-PSTAT3 (tyrosine 705) antibody (BD) following the manufacturer's instructions (BD). Data were acquired on a LSR II or a Canto II cytometer and analyzed with FlowJo software (Tree Star, Inc.).
###end p 56
###begin title 57
ELISA and electrochemiluminescence assay.
###end title 57
###begin p 58
###xml 98 99 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 102 107 <span type="species:ncbi:9606">Human</span>
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
IL-17F electrochemiluminescence assay and IFN-gamma ELISA were performed as previously described (9). Human IL-17, IL-22, CCL20, IL-10, IL-1beta, and mouse IL-17 ELISA kits were obtained from R&D Systems. IL-23 electrochemiluminescence assay was developed in-house with biotinylated anti-IL-23p19 and -IL-23p40. The lower limit of quantitation of this assay was 6 pg/ml and had no cross-reactivity to IL-12p40 up to 4 microg/ml or to IL-12p40/p35 heterodimer up to 5 microg/ml, which were the highest concentrations tested.
###end p 58
###begin title 59
Real-time quantitative PCR.
###end title 59
###begin p 60
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
Real-time quantitative PCR was performed as previously described (9).
###end p 60
###begin title 61
Statistics.
###end title 61
###begin p 62
Wilcoxon signed-rank test or one-way ANOVA (for multiple groups) with a Friedman test was used for statistical analysis. P values of 0.05 or less were considered significant, and all data are represented as mean + the SEM.
###end p 62
###begin title 63
Online supplemental material.
###end title 63
###begin p 64
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 30 35 <span type="species:ncbi:9606">human</span>
Fig. S1 depicts the purity of human naive CD4+CD45RA+ T cells after isolation. Fig. S2 shows the enhancing effects of PGE2 and dibutyryl-cAMP on Th17 cytokines expression in Th17 cells polarized in the presence of IL-1beta and IL-23. Online supplemental material is available at .
###end p 64
###begin title 65
Supplementary Material
###end title 65
###begin title 66
[Supplemental Material Index]
###end title 66
###begin p 67
We thank Bela Desai, Steve Jungers, and Fran Shen for cell sorting; Deepa Prabhavalkar and Wolfgang Seghezzi for IL-23 assay; Eddie Bowman for chemotaxis assays; and Jennifer Louten for helpful discussions.
###end p 67
###begin p 68
Schering-Plough Biopharma is a division of Schering-Plough Corporation. All authors were employed by Schering-Plough at the time of these studies. The authors have no further conflicting financial interests.
###end p 68
###begin article-title 69
The development of COX2 inhibitors.
###end article-title 69
###begin article-title 70
Prostaglandins as modulators of immunity.
###end article-title 70
###begin article-title 71
IL-17 family cytokines and the expanding diversity of effector T cell lineages.
###end article-title 71
###begin article-title 72
T(H)-17 cells in the circle of immunity and autoimmunity.
###end article-title 72
###begin article-title 73
Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells.
###end article-title 73
###begin article-title 74
Understanding the IL-23-IL-17 immune pathway.
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation.
###end article-title 75
###begin article-title 76
###xml 38 43 <span type="species:ncbi:9606">human</span>
Phenotypic and functional features of human Th17 cells.
###end article-title 76
###begin article-title 77
###xml 46 51 <span type="species:ncbi:9606">human</span>
Development, cytokine profile and function of human interleukin 17-producing helper T cells.
###end article-title 77
###begin article-title 78
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.
###end article-title 78
###begin article-title 79
###xml 131 136 <span type="species:ncbi:9606">human</span>
Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.
###end article-title 79
###begin article-title 80
###xml 41 46 <span type="species:ncbi:9606">human</span>
Distinct regulation of interleukin-17 in human T helper lymphocytes.
###end article-title 80
###begin article-title 81
The link between IL-23 and Th17 cell-mediated immune pathologies.
###end article-title 81
###begin article-title 82
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis.
###end article-title 82
###begin article-title 83
The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis.
###end article-title 83
###begin article-title 84
Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells.
###end article-title 84
###begin article-title 85
###xml 75 80 <span type="species:ncbi:9606">human</span>
Prostaglandin E2 (PGE2) synergistically with interleukin-23 (IL-23) favors human Th17 expansion.
###end article-title 85
###begin article-title 86
###xml 47 52 <span type="species:ncbi:9606">human</span>
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.
###end article-title 86
###begin article-title 87
EP2 and EP4 prostanoid receptor signaling.
###end article-title 87
###begin article-title 88
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.
###end article-title 88
###begin article-title 89
In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells.
###end article-title 89
###begin article-title 90
Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma).
###end article-title 90
###begin article-title 91
IL-10 or not IL-10: that is the question.
###end article-title 91
###begin article-title 92
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.
###end article-title 92
###begin article-title 93
###xml 73 78 <span type="species:ncbi:9606">human</span>
Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes.
###end article-title 93
###begin article-title 94
Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5.
###end article-title 94
###begin article-title 95
Modulation of T-cell cytokine secretion by accessory cell-derived products.
###end article-title 95
###begin article-title 96
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
###end article-title 96
###begin article-title 97
###xml 23 28 <span type="species:ncbi:9606">human</span>
Regulation of IL-17 in human CCR6+ Effector memory T cells.
###end article-title 97
###begin article-title 98
###xml 23 28 <span type="species:ncbi:9606">human</span>
The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.
###end article-title 98
###begin article-title 99
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
###end article-title 99
###begin article-title 100
Transforming growth factor-beta induces development of the T(H)17 lineage.
###end article-title 100
###begin article-title 101
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
###end article-title 101
###begin article-title 102
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.
###end article-title 102
###begin article-title 103
Celecoxib: a review of its use in the management of arthritis and acute pain.
###end article-title 103
###begin article-title 104
Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis.
###end article-title 104
###begin article-title 105
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
###end article-title 105
###begin article-title 106
###xml 114 117 <span type="species:ncbi:10116">rat</span>
Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.
###end article-title 106
###begin article-title 107
Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2.
###end article-title 107
###begin article-title 108
Role of IL-10 in the crossregulation of prostaglandins and cytokines in monocytes.
###end article-title 108
###begin article-title 109
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells.
###end article-title 109
###begin article-title 110
A role for macrophage inflammatory protein-3 alpha/CC chemokine ligand 20 in immune priming during T cell-mediated inflammation of the central nervous system.
###end article-title 110
###begin article-title 111
Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis.
###end article-title 111
###begin article-title 112
Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.
###end article-title 112
###begin article-title 113
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
###end article-title 113
###begin article-title 114
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.
###end article-title 114
###begin article-title 115
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor.
###end article-title 115
###begin article-title 116
###xml 29 34 <span type="species:ncbi:9606">human</span>
Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation.
###end article-title 116
###begin article-title 117
Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10.
###end article-title 117
###begin article-title 118
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
Sensitivity difference to the suppressive effect of prostaglandin E2 among mouse strains: a possible mechanism to polarize Th2 type response in BALB/c mice.
###end article-title 118
###begin article-title 119
###xml 46 51 <span type="species:ncbi:9606">human</span>
TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells.
###end article-title 119
###begin article-title 120
Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells.
###end article-title 120
###begin article-title 121
Developmental switches in chemokine response profiles during B cell differentiation and maturation.
###end article-title 121
###begin p 122
Abbreviations used: COX2, cyclooxygenase 2; CRE, cAMP-responsive element; IBD, inflammatory bowel disease; PGE2, prostaglandin E2; ROR, retinoic acid receptor-related orphan receptor.
###end p 122

